Pharmacokinetics, bioavailability, and plasma protein binding study of glytrexate, a novel multitarget antifolate

Glytrexate, developed by our team, as a novel multitarget folate antagonist, has inhibitory effects on a variety of cancer cell types, especially KB tumor cells (IC(50) 0.078 nM), and thus has antitumor drug development prospects. However, its pharmacokinetics and plasma protein binding properties r...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Jiahong, Wu, Mengqi, Wang, Jianchao, Lin, Mengmeng, Sun, Mengmeng, Li, Xin, Xing, Ruijuan, Guo, Ran, Gu, Jianmin, Lyu, Tao, Wang, Lei, Shi, Xiaowei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577195/
https://www.ncbi.nlm.nih.gov/pubmed/36267288
http://dx.doi.org/10.3389/fphar.2022.1001308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577195/
https://www.ncbi.nlm.nih.gov/pubmed/36267288
http://dx.doi.org/10.3389/fphar.2022.1001308

Ejemplares similares